- About
- Resource Library
- Collections
- Events
Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
Agitation associated with Alzheimer’s Dementia (AAD) lead to worsening outcomes in an already devastating disease. A patient-centered focus is recommended for a comprehensive treatment plan. In this webinar, the speakers will review the burden of AAD, then discuss current treatment recommendations and unmet needs.
Objectives:
- Review the economic and caregiver burden related to agitation associated with Alzheimer’s Disease (AAD)
- List the currently available treatment recommendations and guidelines for AAD treatment recommendations
- Identify gaps with current treatment options, both pharmacologic and nonpharmacologic
W. Clay Jackson, MD, DipTh
Assistant Professor of Clinical Psychiatry & Family Medicine University of TN College of Medicine
Bryan Archuleta, PharmD (OPDC)
Senior Long-Term Care Clinical & Scientific Liaison
Speaker W. Clay Jackson, MD, DipTh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Bryan Archuleta, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Related Events
Registration
- Resource Library
